RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
Phase of Trial: Phase IV
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms RIFTOS MKI
- Sponsors Bayer
- 01 Sep 2017 According to a Bayer media release, European sub-group analysis data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
- 07 Jul 2017 Planned End Date changed from 1 Jul 2020 to 31 Jul 2020.
- 06 Jun 2017 Interim results (n=274) assessing use of multikinase inhibitors presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.